Mycobacterium tuberculosis contains mannosylated cell wall components which are important in macrophage recognition and response. The building block for the mannosyl constituents of these components is GDP-mannose, which is synthesized through a series of enzymes involved in the mannose donor biosynthesis pathway. Nothing is known about the expression levels of the genes encoding these enzymes during the course of infection. To generate transcriptional profiles for the mannose donor biosynthesis genes from virulent M. tuberculosis and attenuated Mycobacterium bovis BCG, bacteria were grown in broth culture and within human macrophages. Our results with broth-grown bacteria show that there are differences in expression of the selected genes between M. tuberculosis and BCG, with increased expression of manC in M. tuberculosis and manA in BCG during stationary-phase growth. Results for M. tuberculosis extracted from within macrophages show that whiB2 is highly expressed and manB and manC are moderately expressed during infection. Rv3256c, Rv3258c, and ppm1 have high expression levels early and decreased expression as the infection progresses. Results with BCG show that, as in M. tuberculosis, whiB2 is highly expressed throughout infection, whereas there is either low expression or little change in expression of the remaining genes studied. Overall, our results show that there is differential regulation of expression of several genes in the mannose donor biosynthesis pathway of M. tuberculosis and BCG grown in broth and within macrophages, raising the possibility that the level of mannose donors may vary during the course of infection and thereby impact the biosynthesis of mannose-containing cell wall molecules.Tuberculosis (TB) kills nearly 2 million people each year and has become the leading cause of death among HIV patients. Although treatments have been available for more than 80 years, inconsistent completion of antibiotic courses has led to resistance to all current anti-TB drugs among bacterial isolates (33). The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of TB, especially in HIV patients, poses a serious threat to the control of TB worldwide. Mycobacterium tuberculosis is the causative agent of TB and possesses a compositionally unique cell wall, which is the target of several TB therapeutics, like isoniazid and ethambutol. The last time a new drug was marketed for TB was 1963 (12), and coupled with the development of resistance, this lack of newer drugs emphasizes a critical need for the discovery of new drug targets in M. tuberculosis.It has long been thought that M. tuberculosis has coevolved with its human host, which is the only known reservoir (29). The complex pathogenicity of this bacterium in the context of its preferred niche is only partially understood. Comparative genomics between virulent strains of M. tuberculosis and the attenuated vaccine strain Mycobacterium bovis BCG have revealed gene deletions in BCG, providing insight into some key determinants ...